Haleon's stock drops as Deutsche Bank warns of changing sales channels and weakening consumer trends.

Haleon shares dropped after Deutsche Bank reiterated its "sell" rating, citing concerns over a shift in consumer trends and weakening demand for the company's OTC health products. Analysts trimmed their target price to 335p and cut earnings estimates for 2026 by 1.8%. They highlighted a potential erosion of margins due to changing sales channels, particularly in the US, and softening demand in cold and flu categories.